Saturday, April 19, 2014

Novadaq highlights game changer for the OR

Novadaq highlights game changer for the OR

October 16, 2012 by · Leave a Comment 

Tweet With adoption of its SPY imaging technologies growing in operating rooms across North America, Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has embarked on a long-term growth plan to image nerves and cancer cells with tissue-binding reagents that could represent a paradigm shift in the OR. “The future of the installed base of SPY technologies will include […]

Analysts up Novadaq price target

Analysts up Novadaq price target

September 27, 2012 by · Leave a Comment 

Tweet Piper Jaffray and RBC Capital Markets raised their price targets on Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) following the company’s upbeat presentations at its “analyst and investor day” meeting in New York. Piper Jaffray raised its target on “overweight-rated” Novadaq to $14 from $10 while RBC moved its target to $12 (Canadian) from $7 and maintained its “sector perform” rating. […]

Transition Therapeutics awaiting competing AD trial results

Transition Therapeutics awaiting competing AD trial results

July 17, 2012 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) and its Alzheimer’s disease (AD) program could get a shot in the arm if two closely watched clinical trials by Eli Lilly and a Pfizer-J&J joint venture show indications that they help patients with mild AD symptoms. The results of these clinical trials are expected to be reported this fall. […]

C. K. Cooper resumes coverage of healthcare

C. K. Cooper resumes coverage of healthcare

March 6, 2012 by · Leave a Comment 

Tweet C. K. Cooper has resumed coverage on the healthcare sector with an initiation of Dusa Pharmaceuticals (NASDAQ:DUSA). “With the addition of Ken Trbovich in January of this year and, the re-initiation of healthcare, we are excited to bring our unique perspective back into this very dynamic space,” Cooper president Alexander Montano said in a […]

Trbovich joins C.K. Cooper’s healthcare research team

Trbovich joins C.K. Cooper’s healthcare research team

January 18, 2012 by · Leave a Comment 

Tweet Ken Trbovich has joined C. K. Cooper & Co., a full-service investment bank, as a senior research analyst in the Healthcare Research Department. Mr. Trbovich has 15 years of equity research experience, including a decade on the sell side exclusively focused on companies in healthcare. Most recently, he spent five years as the U.S. […]

IMRIS prices $52.5 million offering

IMRIS prices $52.5 million offering

November 19, 2010 by · Leave a Comment 

Tweet IMRIS (TSX:IM; NASDAQ:IMRS) priced a public offering of 10.5 million common shares at $5 (U.S.) a share to raise $52.5 million in connection with listing its shares on the NASDAQ Global Market. An additional 500,000 shares are being sold by a certain selling shareholder of IMRIS at the same price. Canaccord Genuity and Lazard […]

IMRIS to list on Nasdaq and sell stock

IMRIS to list on Nasdaq and sell stock

November 8, 2010 by · Leave a Comment 

Tweet IMRIS (TSX:IM) has filed a registration statement as part of an IPO in the U.S. and has received conditional approval to list its common shares on the NASDAQ Global Market under the symbol IMRS. IMRIS proposes to offer 10 million common shares and certain selling shareholders propose to offer 3.7 million shares through a […]

Oncolytics in $25 million bought deal

Oncolytics in $25 million bought deal

October 28, 2010 by · Leave a Comment 

Tweet A group of underwriters have agreed to purchase 5.44 million units of Oncolytics Biotech (TSX:ONC; NASDAQ:ONCY) in a bought deal at a price of $4.60 each for total proceeds of about $25 million. Each unit consists of one common share and one-half of a warrant, with each whole warrant entitling the holder to buy […]

RBC ups MDS to outperform

RBC ups MDS to outperform

October 21, 2010 by · Leave a Comment 

Tweet Citing an improved outlook and enhanced supply of molybdenum-99, RBC Capital Markets has upgraded MDS (NYSE:MDZ; TSX:MDS) to “outperform” from “sector perform,” raising its target price to $14 (U.S.) from $10.50. Analyst Doug Miehm writes that MDS has exited a “difficult transitional period associated with asset divestitures,” which will soon be completed, has the […]

MDS buys back 44.1% of stock outstanding

MDS buys back 44.1% of stock outstanding

March 31, 2010 by · Leave a Comment 

Tweet MDS (TSX:MDS; NYSE:MDZ) has released results of its modified Dutch auction and will purchase for cancellation 52.9 million shares at a price of $8.50 (U.S.) each or $450 million. The shares represent 44.1% of the common stock currently outstanding, which will reduce the company’s shares outstanding to about 67.2 million.  RBC Capital Markets acted […]

Next Page »

Google+